Loading…
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy
Summary Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD)...
Saved in:
| Published in: | British journal of haematology 2022-01, Vol.196 (2), p.368-373 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3 |
| container_end_page | 373 |
| container_issue | 2 |
| container_start_page | 368 |
| container_title | British journal of haematology |
| container_volume | 196 |
| creator | Loke, Justin Metzner, Marlen Boucher, Rebecca Jackson, Aimee Hopkins, Louise Pavlu, Jiri Tholouli, Eleni Drummond, Mark Peniket, Andy Bishop, Rebecca Fox, Sonia Vyas, Paresh Craddock, Charles |
| description | Summary
Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance. |
| doi_str_mv | 10.1111/bjh.17823 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2570111946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2570111946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EokvhwAsgS1zgkNaOk9g-wgpaUCUucI4cZ7aZrRMvtkMVTjwCb8I78ST1dhcOSPhiefT508z8hDzn7Iznc95thzMuVSkekBUXTV2UvOIPyYoxJgvOKnVCnsS4ZYwLVvPH5ERUlWZNKVbk19qPHU4moZ9o8CP2sIs4UTP11Hw3FhP2OAFNAwSzWyhGegvO0eRdLiTo70nrcEJrnFuosQm_Ad0r-tmljGMa6IDXw-8fPwPGm0zMCei4gPPYUwfzjYERTf4CDq-xc0A3PuRnginuXXaA0R8beEoebYyL8Ox4n5Iv7999Xl8WV58uPqzfXBVWKCUKo7q6F5JZzWTZicaAYl1nLKs1cFFqaWplNG-a2gpZCwOVgUZqLXu5YUZ34pS8Onh3wX-dIaZ2xGjz5GYCP8e2rCXLq9dVk9GX_6BbP4cpd9eWDVeqVpXmmXp9oGzwMQbYtLuAowlLy1m7T7HNKbb3KWb2xdE4dyP0f8k_sWXg_ADcooPl_6b27cfLg_IObpqrEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618858491</pqid></control><display><type>article</type><title>Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy</title><source>Wiley</source><creator>Loke, Justin ; Metzner, Marlen ; Boucher, Rebecca ; Jackson, Aimee ; Hopkins, Louise ; Pavlu, Jiri ; Tholouli, Eleni ; Drummond, Mark ; Peniket, Andy ; Bishop, Rebecca ; Fox, Sonia ; Vyas, Paresh ; Craddock, Charles</creator><creatorcontrib>Loke, Justin ; Metzner, Marlen ; Boucher, Rebecca ; Jackson, Aimee ; Hopkins, Louise ; Pavlu, Jiri ; Tholouli, Eleni ; Drummond, Mark ; Peniket, Andy ; Bishop, Rebecca ; Fox, Sonia ; Vyas, Paresh ; Craddock, Charles</creatorcontrib><description>Summary
Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance.</description><identifier>ISSN: 0007-1048</identifier><identifier>ISSN: 1365-2141</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.17823</identifier><identifier>PMID: 34490623</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>acute myeloid leukaemia ; Acute myeloid leukemia ; Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Azacitidine - administration & dosage ; Chemotherapy ; Clinical Decision-Making ; clinical trial ; Cytogenetic Analysis ; Depsipeptides - administration & dosage ; Disease Management ; Disease Susceptibility ; early phase ; Female ; Hematology ; Histone deacetylase ; Humans ; hypomethylating agent ; Leukemia ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - etiology ; Male ; Molecular Targeted Therapy ; Prognosis ; refractory ; relapsed ; Remission ; Treatment Outcome ; Young Adult</subject><ispartof>British journal of haematology, 2022-01, Vol.196 (2), p.368-373</ispartof><rights>2021 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3</citedby><cites>FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3</cites><orcidid>0000-0002-0725-069X ; 0000-0001-5041-6678</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34490623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loke, Justin</creatorcontrib><creatorcontrib>Metzner, Marlen</creatorcontrib><creatorcontrib>Boucher, Rebecca</creatorcontrib><creatorcontrib>Jackson, Aimee</creatorcontrib><creatorcontrib>Hopkins, Louise</creatorcontrib><creatorcontrib>Pavlu, Jiri</creatorcontrib><creatorcontrib>Tholouli, Eleni</creatorcontrib><creatorcontrib>Drummond, Mark</creatorcontrib><creatorcontrib>Peniket, Andy</creatorcontrib><creatorcontrib>Bishop, Rebecca</creatorcontrib><creatorcontrib>Fox, Sonia</creatorcontrib><creatorcontrib>Vyas, Paresh</creatorcontrib><creatorcontrib>Craddock, Charles</creatorcontrib><title>Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance.</description><subject>acute myeloid leukaemia</subject><subject>Acute myeloid leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Azacitidine - administration & dosage</subject><subject>Chemotherapy</subject><subject>Clinical Decision-Making</subject><subject>clinical trial</subject><subject>Cytogenetic Analysis</subject><subject>Depsipeptides - administration & dosage</subject><subject>Disease Management</subject><subject>Disease Susceptibility</subject><subject>early phase</subject><subject>Female</subject><subject>Hematology</subject><subject>Histone deacetylase</subject><subject>Humans</subject><subject>hypomethylating agent</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>Male</subject><subject>Molecular Targeted Therapy</subject><subject>Prognosis</subject><subject>refractory</subject><subject>relapsed</subject><subject>Remission</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0007-1048</issn><issn>1365-2141</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kcFu1DAQhi0EokvhwAsgS1zgkNaOk9g-wgpaUCUucI4cZ7aZrRMvtkMVTjwCb8I78ST1dhcOSPhiefT508z8hDzn7Iznc95thzMuVSkekBUXTV2UvOIPyYoxJgvOKnVCnsS4ZYwLVvPH5ERUlWZNKVbk19qPHU4moZ9o8CP2sIs4UTP11Hw3FhP2OAFNAwSzWyhGegvO0eRdLiTo70nrcEJrnFuosQm_Ad0r-tmljGMa6IDXw-8fPwPGm0zMCei4gPPYUwfzjYERTf4CDq-xc0A3PuRnginuXXaA0R8beEoebYyL8Ox4n5Iv7999Xl8WV58uPqzfXBVWKCUKo7q6F5JZzWTZicaAYl1nLKs1cFFqaWplNG-a2gpZCwOVgUZqLXu5YUZ34pS8Onh3wX-dIaZ2xGjz5GYCP8e2rCXLq9dVk9GX_6BbP4cpd9eWDVeqVpXmmXp9oGzwMQbYtLuAowlLy1m7T7HNKbb3KWb2xdE4dyP0f8k_sWXg_ADcooPl_6b27cfLg_IObpqrEQ</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Loke, Justin</creator><creator>Metzner, Marlen</creator><creator>Boucher, Rebecca</creator><creator>Jackson, Aimee</creator><creator>Hopkins, Louise</creator><creator>Pavlu, Jiri</creator><creator>Tholouli, Eleni</creator><creator>Drummond, Mark</creator><creator>Peniket, Andy</creator><creator>Bishop, Rebecca</creator><creator>Fox, Sonia</creator><creator>Vyas, Paresh</creator><creator>Craddock, Charles</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0725-069X</orcidid><orcidid>https://orcid.org/0000-0001-5041-6678</orcidid></search><sort><creationdate>202201</creationdate><title>Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy</title><author>Loke, Justin ; Metzner, Marlen ; Boucher, Rebecca ; Jackson, Aimee ; Hopkins, Louise ; Pavlu, Jiri ; Tholouli, Eleni ; Drummond, Mark ; Peniket, Andy ; Bishop, Rebecca ; Fox, Sonia ; Vyas, Paresh ; Craddock, Charles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>acute myeloid leukaemia</topic><topic>Acute myeloid leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Azacitidine - administration & dosage</topic><topic>Chemotherapy</topic><topic>Clinical Decision-Making</topic><topic>clinical trial</topic><topic>Cytogenetic Analysis</topic><topic>Depsipeptides - administration & dosage</topic><topic>Disease Management</topic><topic>Disease Susceptibility</topic><topic>early phase</topic><topic>Female</topic><topic>Hematology</topic><topic>Histone deacetylase</topic><topic>Humans</topic><topic>hypomethylating agent</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>Male</topic><topic>Molecular Targeted Therapy</topic><topic>Prognosis</topic><topic>refractory</topic><topic>relapsed</topic><topic>Remission</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loke, Justin</creatorcontrib><creatorcontrib>Metzner, Marlen</creatorcontrib><creatorcontrib>Boucher, Rebecca</creatorcontrib><creatorcontrib>Jackson, Aimee</creatorcontrib><creatorcontrib>Hopkins, Louise</creatorcontrib><creatorcontrib>Pavlu, Jiri</creatorcontrib><creatorcontrib>Tholouli, Eleni</creatorcontrib><creatorcontrib>Drummond, Mark</creatorcontrib><creatorcontrib>Peniket, Andy</creatorcontrib><creatorcontrib>Bishop, Rebecca</creatorcontrib><creatorcontrib>Fox, Sonia</creatorcontrib><creatorcontrib>Vyas, Paresh</creatorcontrib><creatorcontrib>Craddock, Charles</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loke, Justin</au><au>Metzner, Marlen</au><au>Boucher, Rebecca</au><au>Jackson, Aimee</au><au>Hopkins, Louise</au><au>Pavlu, Jiri</au><au>Tholouli, Eleni</au><au>Drummond, Mark</au><au>Peniket, Andy</au><au>Bishop, Rebecca</au><au>Fox, Sonia</au><au>Vyas, Paresh</au><au>Craddock, Charles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2022-01</date><risdate>2022</risdate><volume>196</volume><issue>2</issue><spage>368</spage><epage>373</epage><pages>368-373</pages><issn>0007-1048</issn><issn>1365-2141</issn><eissn>1365-2141</eissn><abstract>Summary
Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34490623</pmid><doi>10.1111/bjh.17823</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0725-069X</orcidid><orcidid>https://orcid.org/0000-0001-5041-6678</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2022-01, Vol.196 (2), p.368-373 |
| issn | 0007-1048 1365-2141 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2570111946 |
| source | Wiley |
| subjects | acute myeloid leukaemia Acute myeloid leukemia Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Azacitidine - administration & dosage Chemotherapy Clinical Decision-Making clinical trial Cytogenetic Analysis Depsipeptides - administration & dosage Disease Management Disease Susceptibility early phase Female Hematology Histone deacetylase Humans hypomethylating agent Leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - etiology Male Molecular Targeted Therapy Prognosis refractory relapsed Remission Treatment Outcome Young Adult |
| title | Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A58%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20romidepsin%20and%20azacitidine%20therapy%20is%20well%20tolerated%20and%20clinically%20active%20in%20adults%20with%20high%E2%80%90risk%20acute%20myeloid%20leukaemia%20ineligible%20for%20intensive%20chemotherapy&rft.jtitle=British%20journal%20of%20haematology&rft.au=Loke,%20Justin&rft.date=2022-01&rft.volume=196&rft.issue=2&rft.spage=368&rft.epage=373&rft.pages=368-373&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.17823&rft_dat=%3Cproquest_cross%3E2570111946%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3883-a8b5d370c9072b36ae80bbac059e13297a58a91665c3753ae4ae67997d7f0a9b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2618858491&rft_id=info:pmid/34490623&rfr_iscdi=true |